PHARMACY

Hi-Tech Pharmacal to market generic Subutex

BY Alaric DeArment

AMITYVILLE, N.Y. Hi-Tech Pharmacal will market a generic version of a drug used to treat opioid dependence, the company said Monday.

 

Hi-Tech announced that it would market buprenorphine hydrochloride in the 2-mg and 8-mg strengths through its Midlothian Labs division. The drug is in the form of a tablet placed under the tongue.

 

 

The tablets are a generic version of Reckitt Benckiser’s Subutex, which had sales of $75 million during the 12-month period ended in June, according to IMS Health.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Four-star general to deliver keynote address at NACDS Foundation’s annual dinner

BY Allison Cerra

ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores announced that a four-star general will deliver the keynote address at its annual dinner.

General Stanley McChrystal, a former commander of U.S. and international forces in Afghanistan and the leader of Joint Special Operations Command, will deliver insights on leadership, as well as his life experiences both personally and on the battlefield, to the dinner’s attendees.

This year’s 12th annual NACDS Foundation dinner will be held Nov. 30 in New York.

“We are honored to have distinguished military leader General Stanley McChrystal as the keynote speaker for this year’s NACDS Foundation dinner,” said NACDS Foundation president Edith Rosato. “His service to his country for 34 years demonstrates his career-commitment to the safety of the American people.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Warner Chilcott acquires rights to Enablex

BY Alaric DeArment

ARDEE, Ireland Drug maker Warner Chilcott will buy the U.S. rights to a treatment for overactive bladder for $400 million, the company said Friday.

 

The drug maker announced that it would terminate its co-promotion agreement with Novartis concerning the drug Enablex (darifenacin) and purchase the rights to sell it in the United States. It may be required to make additional milestone payments of up to $20 million to Novartis.

 

 

“This is an important step in expanding our presence in one of our key therapeutic segments,” Warner Chilcott president and CEO Roger Boissonneault said. “The acquisition of the U.S. rights to Enablex bolsters our franchise in the urology segment, provides us with greater control in promoting the product and demonstrates our ability to successfully add complementary assets to an already strong product portfolio.”

 

 

To finance the deal and other corporate expenses, Warner Chilcott also said Friday it would issue bonds worth $500 million.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?